To investigate whether anti-CSPG4-(PDD) had the potential to abolish, rather than restrict tumor growth with one dose, a further in vivo study was performed in which athymic nude mice were challenged with A375 subcutaneous human melanoma xenografts and then treated with 5 mg/kg anti-CSPG4-(PDD), PBS or isotype-(PDD) ADC control. Here, CSPG4 is linked to neoplasm.